Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma

Journal of Surgical Oncology

Volumn 93, Issue 2, 2006, Pages 151-160

  Roca, Fernanda ^a   Mauro, Laura V ^a   Morandi, Ana ^b   Bonadeo, Fernando ^b   Vaccaro, Carlos ^b   Quintana, Guillermo Ojea ^b   Specterman, Sergio ^b   Joffé, Elisa Bal De Kier ^a   Pallotta, María Guadalupe ^b   Puricelli, Lydia Inés ^a   Lastiri, José ^b  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Colorectal cancer; E cadherin; Metalloproteinases; TIMPS; Tumor marker

Indexed keywords

BETA CATENIN; FLUOROURACIL; FOLINIC ACID; GELATINASE B; MATRILYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BETA CATENIN; CADHERINS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 32544438318     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20413     Document Type: Article

References (44)

1. Matos E, Loria D, Zengarini N, et al.: Atlas de Mortalidad por Cáncer. Argentina 1997-2001. Buenos Aires, Matos E and Loria D, 2003.
2. Flatmark K, Bjornland K, Johannessen HO, et al.: Study group for micrometastases in BM in colorectal cancer. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 2002;8:444-449.
3. Compton CC: The pathology report in colorectal cancer: A user's guide. Pathology report in colorectal cancer. Proceedings of the 39th American Society of Clinical Oncology (ASCO) Annual Meeting 2003; 502-516.
4. Shiozaki H, Oka H, Inoue M, et al.: E-cadherin mediated adhesion system in cancer cells. Cancer 1996;77:1605-1613.
5. Cadigan KM, Nusse R: Wnt signaling: A common theme in animal development. Genes Dev 1997;11:3286-3305.
6. Peifer M, Polakis P: Wnt signaling in oncogenesis and embryogenesis-A look outside the nucleus. Science 2000;287: 1606-1609.
7. Tetsu O, Mc Cormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
8. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al.: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
9. Friedl P, Wolf K: Tumor-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-373.
10. Kermorgant S, Aparicio T, Dessirier V, et al.: Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 2001;22:1035-1042.
11. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
12. Skiles JW, Gonnella NC, Jeng AY: The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001;8:425-474.
13. Shimoyama Y, Hirohashi S, Hirano A, et al.: Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 1989;49:23-28.
14. Shiozaki H, Tahara H, Oka H, et al.: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991;139:17-23.
15. Takayama T, Shiozaki H, Shibamoto S, et al.: β-catenin expression in human cancers. Am J Pathol 1996;148:39-46.
16. Furuta K, Yoshioka S, Okabe S, et al.: Expressions of two adenomatous polyposis coli and E-cadherin proteins on human colorectal cancers. Virchows Arch 2003;442:266-270.
17. Kudo Y, Kitajima S, Ogawa I, et al.: Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 2004;10:5455-5463.
18. Takayama T, Shizaki H, Doki Y, et al.: Aberrant expression and phosphorylation of beta-catenin in human colorectal cancer. Br J Cancer 1998;77:605-613.
19. Dorudi S, Sheffield JP, Poulsom R, et al.: E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993;142:981-986.
20. Aoki S, Shimamura T, Shibata T, et al.: Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer 2003;88:726-732.
21. Mohri Y: Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg Today 1997;27:606-612.
22. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al.: Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004;15:1535-1542.
23. Lin YC, Wu MY, Li DR, et al.: Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and cyclin D(1) expression in human esophageal squamous cell carcinoma. World J Gastroenterol 2004;10: 3235-3239.
24. Inagawa S, Itabashi M, Adachi S, et al.: Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: Correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-456.
25. Morin PJ, Sparks AB, Korinek V, et al.: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790.
26. Ilyas M, Tomlinson IP, Rowan A, et al.: β-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997;94:10330-10334.
27. Ikeda S, Kishida M, Matsuura Y, et al.: GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2 A complexed with AXIN. Oncogene 2000;19:537-545.
28. Mikami T, Mitomi H, Hara A, et al.: I. Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasm. Cancer 2000;89:733-740.
29. Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-564.
30. Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-117.
31. Bernardo MM, Fridman R: TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003; 374:739-745.
32. Fridman R, Toth M, Pena D, et al.: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55:2548-2555.
33. Sier CF, Kubben FGM, Ganesh S, et al.: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;73: 413-417.
34. Kallakury BVS, Karikehalli S, Haholu A, et al.: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognosis variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-3119.
35. Wilson CL, Matrisian LM: Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-136.
36. Imai K, Yokohama Y, Nakanishi I, et al.: Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-6697.
37. Newell KJ, Witty JP, Rodgers WH, et al.: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994;10:199-206.
38. Kioi M, Yamamoto K, Higashi S, et al.: Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003;22:8662-8670.
39. Brabletz T, Jung A, Dag S, et al.: Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-1038.
40. Sier CFM, Kubben FJGM, Ganesh S, et al.: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-417.
41. Corcoran ML, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a c-AMP-dependent mechanism. J Biol Chem 1995;270:13453-13459.
42. Guedez L, Stetler-Stevenson WG, Wolff L, et al.: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-2010.
43. Grignon DJ, Sakr W, Toth M, et al.: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56: 1654-1659.
44. Murashige M, Miyahara M, Shiraishi N, et al.: Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 1996;26:303-309.